CTLA4 and cancer: Combination therapies manipulating the early regulator of T cell self‐reactivity (CTLA‐4) and a later regulator of T cell exhaustion (PD‐1) have produced outstanding results in cancer, albeit with autoimmune side effects (Larkin et al, 2019).